Joseph Uberti is an Oncology physician affiliated with The Barbara Ann Karmanos Cancer Institute. OpenAlex indexes 288 publications with 4,875 citations (h-index 33).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4100 John R
Karmanos Cancer Center
Detroit, MI 482012013
Telephone
800-527-6266Registry record last updated 5 Jan 2017.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
32.8%Leukocyte Growth Factor13.3%Zarxio100%Part D<11 patientsCalcineurin inhibitor10.9%Tacrolimus100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
27.3%Osmotically acting laxatives17.2%Magnesium Sulfate100%Part D<11 patientsAntidiarrheal microorganisms10.2%Folic Acid100%Part D<11 patientsDermatology
18%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor18%Acyclovir100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2022–2024 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Post-transplant Cyclophosphamide Versus Thymoglobulin in HLA-Mismatched Unrelated Donor Transplant for Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Biology of Blood and Marrow Transplantation
2021 - Age and gender differences in financial distress among hematopoietic cell transplant survivors
Supportive Care in Cancer
2020 - A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease
Biology of Blood and Marrow Transplantation
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Charles Schiffer, MD
The Barbara Ann Karmanos Cancer Institute
Jose Larios, MD
The Barbara Ann Karmanos Cancer Institute
Borys Hrinczenko, MD
The Barbara Ann Karmanos Cancer Institute
Andrew Kin, MD
The Barbara Ann Karmanos Cancer Institute
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”